Compare DexCom, Inc. (DXCM) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? DexCom, Inc. trades at $77.2 (market cap $28.06B), while MONDELEZ INTERNATIONAL INC Common Stock trades at $61.22 (market cap $75.38B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 2.7× DexCom, Inc.'s market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.41% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | MDLZ | |
|---|---|---|
Market Cap | $28.06B | $75.38B |
Sector | Health | Consumer Staples |
52-Week High | $89.53 | $70.75 |
52-Week Low | $54.84 | $51.51 |
Enterprise Value | $27.03B | $95.47B |
Dividend Yield | — | 3.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Mondelez International (MDLZ) trades at $60.48, up 2.86% with a bearish technical signal despite recent earnings beats. The company reported 2025 revenue of $38.54B with a net income margin of 6.64%, while valuation ratios like P/E of 29.07 suggest premium pricing. Analyst consensus is strongly bullish with a $68.00 price target, supported by innovation in brands like Oreo and Ritz. A dividend of $0.50 per share is scheduled for July 2026, enhancing income appeal amid stable cash flows.
Outlook remains positive due to consistent earnings outperformance and strategic brand initiatives, though risks include margin pressure from input costs and technical bearish indicators. The stock offers growth potential with a margin of safety from analyst targets, but investors should monitor Q2 2026 results on July 28 for volume growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
